Investor Relations | Alnylam Pharmaceuticals, Inc.

Learn more about Alnylam’s response to COVID-19 ›

EVENTS & PRESENTATIONS

Apr 08, 2025 / 11:45 AM EDT

Needham 24th Annual Virtual Healthcare Conference

Feb 25, 2025

Alnylam 2025 R&D Day

Past Events ›

Feb 13, 2025

Alnylam Pharmaceuticals Q4 2024 Earnings Conference Call

Past Events ›

View all events and presentations ›

2024 Annual Report

2023 Corporate Responsibility Report

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q4 2024 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

2025 Proxy Statement LEARN MORE ›

View all resources and documents ›

PRESS RELEASES

Apr 01, 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Mar 29, 2025

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

Mar 28, 2025

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

View all press releases ›